SR-9009
Stenabolic · SR9009
Half-life
4 hr
Time to Peak
30 min
Steady State
~1 days
Dose Range
5–30 mg
Frequency
three times daily
Overview
Rev-Erb alpha/beta agonist. Not technically a SARM but grouped with them in community usage. Originally developed at Scripps Research Institute. Community interest: claimed to mimic exercise adaptations (mitochondrial biogenesis, improved endurance, fat oxidation) without being androgenic. Critical note: oral bioavailability in rats is very poor (~2%). Community uses injectable form specifically because oral SR-9009 may not reach meaningful plasma concentrations. Harm reduction: Very short half-life (~4 hours) requires 3–4 daily doses (injectable) or 2–3 daily (oral). No human data — all effects extrapolated from mouse models. No HPG suppression (not androgenic). Not controlled in most jurisdictions. Research compound only.
Mechanism of Action
Agonist of Rev-Erb alpha and beta nuclear receptors (circadian clock regulators). Modulates expression of genes governing mitochondrial biogenesis, glucose metabolism, and lipid oxidation. Non-androgenic — does not bind AR. Poor oral bioavailability drives community preference for injectable form.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Intramuscular (IM) | 5–30 mg | 4 hr | 30 min | three times daily, four times daily |
| Oral | 10–40 mg | 4 hr | 1 hr | three times daily, four times daily |
Storage & Handling
Room temperature — Store below 25C. Protect from light. Injectable: DMSO or oil-based suspension. Oral: PEG400 or liquid suspension.
Used in Regimens
SR-9009 is not currently part of any catalog regimen.
Data Sources
- Community r/steroids Compound Experience Directory
Related Tools
Track SR-9009 with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.